Drug intelligence / Profile preview

BMN 370

Development stage: Preclinical
Lead developer: BioMarin
Modality: Recombinant Proteins and Enzymes
Administration: Subcutaneous

Overview

BMN 370 is an investigational drug being developed by BioMarin Pharmaceutical for the treatment of von Willebrand disease (vWD). It is designed as a single subcutaneous injection with the potential to normalize bleeding events in patients with vWD. The drug is currently in preclinical or early clinical development, with a targeted Investigational New Drug (IND) application planned for late 2025. The specific mechanism of action has not been publicly disclosed, but it is described as having a unique approach aimed at addressing bleeding associated with low levels of von Willebrand factor[1][2][3][4].

Targets

BB-031 (Von Willebrand factor)

Beyond the preview

Go deeper on BMN 370.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BMN 370.

Explore the full profile